Aarti Drugs Limited

rs,

24/83 October 19, 2023 To, Listing/ Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 BSE CODE: 524348 To, Listing/ Compliance Department National St

Rs. 100 crore

Listed On National Stock Exchange of India Limited 2017 Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2014 2023 Consolidated Revenue Rs. 2,700+ Cr 2020 Crossed Rs. 2,000 Cr Consolidate

Rs. 2,700

Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2014 2023 Consolidated Revenue Rs. 2,700+ Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed

Rs. 2,000

d. crossed Rs. 100 crores turnover 2014 2023 Consolidated Revenue Rs. 2,700+ Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT

Rs. 200

014 2023 Consolidated Revenue Rs. 2,700+ Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover

Rs. 200

Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subsi

Rs. 1,000 crore

idated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 199

100%

ed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 1998 Crossed Rs. 100 crores turnover 7 Key Fact

Rs. 100 crore

formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 1998 Crossed Rs. 100 crores turnover 7 Key Facts & Figures Largest producer of Nimesulide in the world. Largest producer

4,261 MT

API Manufacturing Largest producer of Ketoconazole in the world 12 Manufacturing Facilities 4,261 MT/Monthly Capacity 80+ Finished Products 1,10,330 Sq.m Plant Area Largest producer of Metronida

38%

330 Sq.m Plant Area Largest producer of Metronidazole Benzoate in the world ~1,571 Employees ~38% Export Revenue Largest producer in Fluoroquinolones group in the world Largest producer of Tin

85%

s in Benzene & Chloro-sulphonic chemistry in the world ▪ 9 manufacturing units ▪ Contributes ~85% revenues ▪ Installed capacity of 40,560 MTPA ▪ Manufacturing plant at Baddi, Himachal Pradesh i

Barriers

1

Revenue

1

Captive consumption

1

Investor Relations Advisor

1

Barriers

Presence in Highly Specialized API Segment 5. Robust Balance Sheet 2. Unique Competitive Position 4. Diversified product and client mix 3. Poised to overcome industry challenges High Entry Barriers : Presence in Highly Specialized API Segment Over a decade, API manufacturing has transitioned towards highly regulated, specialized business How API Manufacturing Has Evolved Impact Regulations ❑ Stringent pharmacopoeia standards ❑ Addition of elemental ❑ Tightened impurity profiling ❑ Rigorous carcinogenicity checks Cost Structure Higher capex requirements to adhere to ever rising quality, environmental & regulatory requirements High R&D costs Tightened Regulations Quality & Environmental Standards Higher Capex Requirements ❑ Lower Competitive Intensity: Various small-scale manufacturers have exited due to unviability of cost structure ❑ High Entry Barriers: High entry barriers for new entrants due to cost structure and compliance requirements ❑ API manufacturing has evolved from a commodi

Captive consumption

Rs. 300 crores Revenue Growth Higher Margins Higher RoCE 29 Product-wise Capex Plans Anti Diabetic ▪ CEP renewed by EDQM in 2022 ▪ Manufacturing over 1,000 TPM making it one of the largest metformin player ▪ Coming up with 1450 TPM capacity via brown field expansion in Q1FY24 ▪ Launch of Gliptins will further strengthen this therapeutic category. ▪ Exploring backward integration options. Antiprotozoal ▪ Further consolidating the position in Indian Market via brown field expansion by about 40% for couple of products ▪ Recently got approval to market the product in China ▪ Incremental expansions and downstream products improvement Vitamins / Anti- Inflammatory ▪ Multi-purpose facility under construction. Targeting highly regulated markets. ▪ Brown field expansion of its existing anti inflammatory products commissioned at the end of FY20 which will drive future growth in this therapeutic category ▪ Installed capacity will give revenues of around Rs. 50 crores / Rs. 35 crores per annum as

Investor Relations Advisor

CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Email: investorrelations@aartidrugs.com Contact no.: +91 22 24048199 Mr. Deven Dhruva / Mr. Harsh Shah E: deven.dhruva@sgapl.net / harsh.shah@sgapl.net T: +91 98333 73300 / +91 97689 74808 www.aartidrugs.co.in www.sgapl.net